SCHEMBL4484170

SCHEMBL4484170

CC(C)NC(=O)c1cc[c]o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.39
ALDH1A1 P00352 4/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
LMNA P02545 1/20 0.39
ALOX15 P16050 1/20 0.39
PTGS2 P35354 1/20 0.39
MLYCD O95822 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
KMT2A Q03164 3/20 0.37
POLB P06746 2/20 0.37
MEN1 O00255 2/20 0.37
ALOX5 P09917 1/20 0.37
KDM4E B2RXH2 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL512220 0.79
SCHEMBL6766816 0.76 KMT2A (0.41) ALDH1A1LMNAMLYCDSMN1; SMN2KMT2A
SCHEMBL4481449 0.74 MAPK1 (0.40) NPC1LMNAKMT2APOLBMEN1
SCHEMBL855237 0.71
SCHEMBL2812848 0.69 TSHR (0.51) ALDH1A1LMNASMN1; SMN2KMT2AMEN1
SCHEMBL6623337 0.69 HPGD (0.45) NPC1ALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL1106975 0.68 KMT2A (0.62) NPC1ALDH1A1LMNAALOX15SMN1; SMN2
SCHEMBL13631427 0.68 HPGD (0.66) NPC1ALDH1A1SMN1; SMN2POLBHPGD
SCHEMBL467358 0.67 MLYCD (0.55) ALDH1A1CYP1A2CYP2C19LMNAALOX15
SCHEMBL13753395 0.67 ALDH1A1 (0.67) NPC1ALDH1A1LMNASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622464-B2 Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-11-24 US claimed
EP-1487828-B1 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES GLAXO GROUP LTD (GB) 2008-11-05 EP claimed
US-20060063765-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2006-03-23 US claimed
US-7622464-B2 Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-11-24 US disclosed
EP-1487828-B1 MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES GLAXO GROUP LTD (GB) 2008-11-05 EP disclosed
US-20060063765-A1 Novel compounds GLAXO GROUP LIMITED (GB) 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063765-A1 Novel compounds CCR3, NSUN3, CCR1 NPC1 931/4885ALDH1A1 2920/4885CYP1A2 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.